ArriVent BioPharma (AVBP) Non-Current Assets (2023 - 2026)
ArriVent BioPharma (AVBP) reported Non-Current Assets of $595000.0 for Q1 2026, down 98.0% on a YoY basis from $29.7 million in Q1 2025, and up 118.75% sequentially from $272000.0 in Q4 2025.
ArriVent BioPharma (AVBP) Non-Current Assets (2023 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 4 years of Non-Current Assets data on file, last reported at $595000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 98.0% year-over-year to $595000.0; the trailing twelve-month figure through Mar 2026 stood at $25.6 million (down 67.37% YoY), and the FY2025 full-year result was $272000.0, down 99.43% from the prior year.
- Non-Current Assets rose to $595000.0 in Q1 2026, from $272000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $48.0 million in Q4 2024 to a low of $272000.0 in Q4 2025.
- A 4-year average of $10.7 million and a median of $1.9 million in 2023 frame the typical range for Non-Current Assets.
- Peak annual rise in Non-Current Assets reached 8198.88% in 2025, while the deepest fall reached 99.43% in 2025.
- Tracing AVBP's Non-Current Assets over 4 years: stood at $3.1 million in 2023, then soared by 1432.36% to $48.0 million in 2024, then tumbled by 99.43% to $272000.0 in 2025, then jumped by 118.75% to $595000.0 in 2026.
- Business Quant data shows AVBP's Non-Current Assets at $595000.0 in Q1 2026, $272000.0 in Q4 2025, and $5.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - | 595,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 595,000.00 |
| Dec 31, 2025 | 272,000.00 |
| Sep 30, 2025 | 5.34 Mn |
| Jun 30, 2025 | 19.36 Mn |
| Mar 31, 2025 | 29.71 Mn |
| Dec 31, 2024 | 47.96 Mn |
| Sep 30, 2024 | 313,000.00 |
| Jun 30, 2024 | 344,000.00 |
| Mar 31, 2024 | 358,000.00 |
| Dec 31, 2023 | 3.13 Mn |